右美托咪定辅助镇静预防严重炎症与脓毒性脑病:一项先导性随机对照研究
这项在瑞士单中心大学医院开展的先导性开放标签随机对照试验,纳入2019年9月1日至2022年6月30日期间ICU收治、需要插管并持续镇静的成人脓毒症患者70例,34例(48.6%)随机分入右美托咪定组、36例(51.4%)分入丙泊酚/咪达唑仑组。主要终点为随机化后48小时血清S100-β水平:右美托咪定组中位数0.103(四分位距0.052-0.194)ng/ml,丙泊酚/咪达唑仑组0.189(0.086-0.368)ng/mL(P=0.064)。其他生物标志物随时间变化无差异。在格拉斯哥昏迷评分≤13分的患者中,右美托咪定组S100-β中位数0.13 ng/mL(0.06-0.18),丙泊酚/咪达唑仑组0.91 ng/mL(0.43-0.96)(P=0.033)。作者结论认为右美托咪定为基础镇静未显著改变S100-β或其他脓毒性脑病标志物,GCS≤13分患者中S100-β较低这一发现需进一步研究。
要点
- 在需要插管和持续镇静的成人脓毒症ICU患者中,右美托咪定为基础镇静组48小时S100-β中位数0.103 ng/ml,丙泊酚/咪达唑仑组0.189 ng/mL,P=0.064,未达统计学显著。
- 格拉斯哥昏迷评分≤13分的亚组中,右美托咪定组S100-β中位数0.13 ng/mL(0.06-0.18),丙泊酚/咪达唑仑组0.91 ng/mL(0.43-0.96),P=0.033。
- 其他生物标志物随时间变化在两组间无差异。
- 作者结论认为右美托咪定为基础镇静与丙泊酚/咪达唑仑为基础镇静相比,S100-β或其他脓毒性脑病标志物均无显著差异。
- 作者指出GCS≤13分患者中右美托咪定组S100-β较低这一发现需进一步研究。
适用人群与场景
- 2019年9月1日至2022年6月30日期间入住瑞士单中心大学医院ICU、需要插管并持续镇静的成人脓毒症患者。
处置流程与药物剂量
- 干预为右美托咪定为基础镇静,对照为丙泊酚和/或咪达唑仑为基础镇静;原文未给出具体剂量、给药途径、频次或目标值。
研究设计与关键结果
- 研究类型为先导性开放标签随机对照临床试验,单中心,样本量70例,右美托咪定组34例(48.6%),丙泊酚/咪达唑仑组36例(51.4%)。
- 主要终点随机化后48小时血清S100-β:右美托咪定组中位数0.103(四分位距0.052-0.194)ng/ml,丙泊酚/咪达唑仑组0.189(0.086-0.368)ng/mL,P=0.064。
- 其他生物标志物随时间变化无差异。
- 格拉斯哥昏迷评分≤13分患者中,右美托咪定组S100-β中位数0.13 ng/mL(0.06-0.18),丙泊酚/咪达唑仑组0.91 ng/mL(0.43-0.96),P=0.033。
证据类型、等级与局限
- 证据类型为先导性开放标签随机对照临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为右美托咪定为基础镇静与丙泊酚/咪达唑仑为基础镇静相比,在需要机械通气的脓毒症危重患者中S100-β或其他脓毒性脑病标志物均无显著差异。
- 作者指出GCS≤13分患者中右美托咪定镇静者S100-β较低这一发现需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Septic encephalopathy (SE) occurs in up to 50% of critically ill patients with sepsis and is associated with a high mortality and morbidity. The pathophysiology of SE is complex and involves increased levels of inflammatory mediators. Commonly used sedative drugs, such as propofol and midazolam, may worsen neuronal inflammation. Dexmedetomidine (DEX) has been shown to decrease the production of inflammatory mediators in experimental models of sepsis. The aim of this study was to investigate the effect of DEX on biomarkers associated with SE in critically ill patients with sepsis.
DESIGN: Pilot, open-label, randomized controlled clinical trial.
SETTING: Single-center University Hospital, Switzerland.
PATIENTS: Adult patients with sepsis admitted to the ICU, who required intubation and ongoing sedative medication between September 1, 2019, and June 30, 2022.
INTERVENTIONS: DEX-based sedation compared with propofol and/or midazolam-based sedation and serum S100-β level at 48 hr after randomization.
MEASUREMENTS AND MAIN RESULTS: The study included 70 participants with 34 (48.6%) randomized to the DEX group and 36 (51.4%) to the propofol/midazolam group. Median S100-β levels in the DEX group at 48 hr were 0.103 (interquartile range 0.052-0.194) ng/ml, and in the propofol/midazolam group 0.189 (0.086-0.368) ng/mL ( p = 0.064). Other biomarker showed no differences over time. In patients with a Glasgow Coma Scale less than or equal to 13, the median S100-β level in the DEX group was 0.13 ng/mL (0.06-0.18) compared to 0.91 ng/mL (0.43-0.96) in the propofol/midazolam group ( p = 0.033).
CONCLUSIONS: DEX-based sedation compared to propofol/midazolam-based sedation did not show any significant difference in S100-β or any other markers of SE in critically ill patients with sepsis requiring mechanical ventilation. The finding of lower S100-β levels in DEX-sedated patients with GCS less than 13 warrants further investigation.
参考来源
- Iten M, Bachmann K, Jakob SM, et al. Adjunctive Sedation with Dexmedetomidine for the Prevention of Severe Inflammation and Septic Encephalopathy: A Pilot Randomized Controlled Study. Crit Care Med. 2025. PMID: 40162868. doi:10.1097/CCM.0000000000006655
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。